Mode
Text Size
Log in / Sign up

Specific microRNAs including miR-338-3p and miR-155-5p serve as robust biomarkers for active pemphigus diseaseSpecific MicroRNAs Show Promise as Biomarkers for Pemphigus Disease

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that miR-338-3p, miR-155-5p, and miR-424-5p show high AUC values as potential biomarkers for active pemphigus.

This systematic review evaluates the expression profiles, target genes, and molecular pathways of specific microRNAs, including miR-338-3p, miR-146a-5p, miR-155-5p, and miR-424-5p, in patients with pemphigus and relevant experimental models. The review identifies miR-338-3p, miR-155-5p, and miR-424-5p as robust diagnostic biomarkers for active disease, with AUC values reaching 0.988. Additionally, miR-338-3p and miR-155-5p levels showed significant positive correlations with PDAI scores.

Mechanistic analysis identified specific target genes for these microRNAs. miR-338-3p was shown to target RNF114, TRADD, and RUNX1, while miR-146a-5p was validated to target NF-kB adaptors TRAF6 and IRAK1. These findings suggest that these microRNAs may play roles in the underlying molecular pathways of the disease.

The authors note that further large-scale and mechanistic studies are necessary to validate functional target genes and confirm the clinical utility of these markers. While these microRNAs may serve as potential therapeutic targets and high-precision tools for clinical stratification and assessing disease severity, their current clinical utility remains to be fully established through broader validation.

Pemphigus is a condition that can cause severe skin and mucous membrane issues. Researchers reviewed data on specific microRNAs, which are small molecules that help regulate genes. The study looked at how these molecules, specifically miR-338-3p, miR-155-5p, miR-424-5p, and miR-146a-5p, relate to the disease.

The review found that miR-338-3p, miR-155-5p, and miR-424-5p could serve as strong indicators of active disease. These markers showed high accuracy in identifying the condition. Additionally, the levels of miR-338-3p and miR-155-5p were linked to scores that measure how severe a patient's symptoms are.

While these findings are promising for creating better ways to track disease severity, the evidence is still early. Because this was a systematic review of existing data, more large-scale studies are needed to confirm how these markers work in a clinical setting. These findings may eventually help doctors better categorize patients and identify potential targets for future treatments.

What this means for you:
Specific microRNAs may help doctors track pemphigus severity, but more large-scale research is needed.

Common questions

What are these microRNAs and how do they relate to pemphigus?

MicroRNAs are small molecules that help control gene activity. This review looked at four specific ones: miR-338-3p, miR-155-5p, miR-424-5p, and miR-146a-5p. The study found that miR-338-3p, miR-155-5p, and miR-424-5p can act as markers to identify active disease and track how severe the symptoms are.

Can these markers be used to treat pemphigus?

The study does not show that these microRNAs can treat the condition. Instead, they are being studied as tools to help doctors identify the disease and measure its severity. Because the research is still in the early stages, more large-scale studies are needed to see how they might be used in a clinic.

How accurate are these markers for diagnosing the disease?

The study found that miR-338-3p, miR-155-5p, and miR-424-5p were robust markers for active disease, with some measurements reaching high accuracy levels. However, the researchers noted that more studies are needed to fully confirm their clinical use and how they function as targets for future treatments.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedOct 2026
View Original Abstract ↓
Pemphigus is a severe autoimmune bullous disease characterized by the production of pathogenic autoantibodies leading to acantholysis. Emerging evidence suggests that microRNA regulate immune responses and may contribute to disease pathogenesis. However, an updated, integrative synthesis linking miRNA expression profiles to their molecular targets remains lacking. This review specifically addresses the expression profiles, target genes, and molecular pathways of miR-338-3p, miR-146a-5p, miR-155-5p and miR-424-5p, and their potential involvement in pemphigus. Original studies investigating microRNA expression or functional roles in patients with pemphigus or relevant experimental models were considered eligible. A literature search was conducted in Scopus, PubMed and ScienceDirect scientific databases between January 2000 and September 2025. Titles, abstracts, and full texts were screened, by two independent researchers according to predefined eligibility criteria. A total of nine studies were included in this review. Clinical evidence establishes miR-338-3p, miR-155-5p, and miR-424-5p as robust diagnostic biomarkers of active disease, with AUC values reaching 0.988. Notably, miR-338-3p and miR-155-5p levels show significant positive correlations with PDAI scores. Mechanistically, for miR-338-3p, the genes RNF114, TRADD, and RUNX1 have been experimentally validated as direct targets, linking this miRNA to Th1/Th2 imbalance and the suppression of FOXP3-mediated Treg activity. Similarly, miR-146a-5p has been validated to target the NF-κB adaptors TRAF6 and IRAK1, acting as an endogenous anti-inflammatory regulator. These findings identify specific miRNA axes as potential therapeutic targets and high-precision tools for clinical stratification and disease severity. However, further large-scale and mechanistic studies are needed to validate their functional target genes and clinical utility.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.